164 related articles for article (PubMed ID: 20496145)
1. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2010 Sep; 66(9):865-70. PubMed ID: 20496145
[TBL] [Abstract][Full Text] [Related]
2. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Keskitalo JE; Kurkinen KJ; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2009 Aug; 68(2):207-13. PubMed ID: 19694740
[TBL] [Abstract][Full Text] [Related]
3. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
[TBL] [Abstract][Full Text] [Related]
4. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2010 May; 66(5):497-502. PubMed ID: 20179914
[TBL] [Abstract][Full Text] [Related]
5. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.
Keskitalo JE; Kurkinen KJ; Neuvoneni PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):457-61. PubMed ID: 19238649
[TBL] [Abstract][Full Text] [Related]
6. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Tapaninen T; Karonen T; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832
[TBL] [Abstract][Full Text] [Related]
7. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects.
Vaidyanathan S; Jermany J; Yeh C; Bizot MN; Camisasca R
Br J Clin Pharmacol; 2006 Dec; 62(6):690-8. PubMed ID: 17118124
[TBL] [Abstract][Full Text] [Related]
8. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
9. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics and pharmacodynamics of aliskiren.
Vaidyanathan S; Jarugula V; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2008; 47(8):515-31. PubMed ID: 18611061
[TBL] [Abstract][Full Text] [Related]
11. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
[TBL] [Abstract][Full Text] [Related]
12. Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.
Jensen BP; Roberts RL; Vyas R; Bonke G; Jardine DL; Begg EJ
Br J Clin Pharmacol; 2012 Apr; 73(4):619-28. PubMed ID: 21999196
[TBL] [Abstract][Full Text] [Related]
13. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
[TBL] [Abstract][Full Text] [Related]
15. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene.
Kimchi-Sarfaty C; Marple AH; Shinar S; Kimchi AM; Scavo D; Roma MI; Kim IW; Jones A; Arora M; Gribar J; Gurwitz D; Gottesman MM
Pharmacogenomics; 2007 Jan; 8(1):29-39. PubMed ID: 17187507
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
Buczko W; Hermanowicz JM
Pharmacol Rep; 2008; 60(5):623-31. PubMed ID: 19066408
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.
Hu P; Bartlett M; Karan RS; Jiang J; Zhang S; Zhang J; Howard D; Yeh CM; Al-Fayoumi S; Jarugula V; Dole WP
Clin Drug Investig; 2010; 30(4):221-8. PubMed ID: 20192280
[TBL] [Abstract][Full Text] [Related]
18. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Magliulo L; Dahl ML; Lombardi G; Fallarini S; Villa LM; Biolcati A; Scordo MG
Eur J Clin Pharmacol; 2011 Jan; 67(1):47-54. PubMed ID: 20931330
[TBL] [Abstract][Full Text] [Related]
19. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.
Aquilante CL; Wempe MF; Sidhom MS; Kosmiski LA; Predhomme JA
Eur J Clin Pharmacol; 2013 Jul; 69(7):1401-9. PubMed ID: 23407853
[TBL] [Abstract][Full Text] [Related]
20. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]